Symbols / /ALDX
/ALDX Chart
About
No company description available for this symbol.
Fundamentals
Scroll to Statements| Sector | — | Industry | — | Market Cap | — |
| Enterprise Value | — | Income | — | Sales | — |
| Book/sh | — | Cash/sh | — | Dividend Yield | — |
| Payout | — | Employees | — | IPO | — |
| P/E | — | Forward P/E | — | PEG | — |
| P/S | — | P/B | — | P/C | — |
| EV/EBITDA | — | EV/Sales | — | Quick Ratio | — |
| Current Ratio | — | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | — | EPS next Y | — | EPS Growth | — |
| Revenue Growth | — | Earnings | — | ROA | — |
| ROE | — | ROIC | — | Gross Margin | — |
| Oper. Margin | — | Profit Margin | — | Shs Outstand | — |
| Shs Float | — | Short Float | — | Short Ratio | — |
| Short Interest | — | 52W High | — | 52W Low | — |
| Beta | — | Avg Volume | — | Volume | — |
| Target Price | — | Recom | — | Prev Close | — |
| Price | — | Change | — |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
—
Latest analyst target
3. DCF / Fair value
—
Simplified FCF or EPS-based estimate
Ratings
No analyst ratings or price targets available.
- Biotech CEO in fireside chat at Oppenheimer health conference - Stock Titan Wed, 18 Feb 2026 08
- Is Aldeyra Therapeutics (ALDX) Outperforming Other Medical Stocks This Year? - Yahoo Finance hu, 26 Feb 2026 08
- HC Wainwright Analysts Boost Earnings Estimates for ALDX - MarketBeat Fri, 06 Mar 2026 12
- Aldeyra Therapeutics: Reproxalap’s March 2026 FDA Decision Is The Defining Catalyst - Seeking Alpha ue, 30 Dec 2025 08
- New Analyst Forecast: $ALDX Given $9.0 Price Target | ALDX Stock News - Quiver Quantitative Mon, 10 Nov 2025 08
- Does Aldeyra Therapeutics (NASDAQ:ALDX) Have A Healthy Balance Sheet? - simplywall.st hu, 27 Nov 2025 08
- Aldeyra Therapeutics Faces FDA PDUFA Date Extension - TipRanks ue, 16 Dec 2025 08
- Is Aldeyra Therapeutics (ALDX) Surpassing Other Healthcare Stocks in Performance This Year? - Bitget hu, 26 Feb 2026 08
- Aldeyra Therapeutics (NASDAQ:ALDX) Stock Passes Below 200-Day Moving Average - Here's What Happened - MarketBeat hu, 19 Feb 2026 08
- Aldeyra Therapeutics, Inc.'s (NASDAQ:ALDX) recent 10% pullback adds to one-year year losses, institutional owners may take drastic measures - Yahoo Finance Mon, 08 Dec 2025 08
- Aldeyra (NASDAQ: ALDX) reports FDA inspections of reproxalap facilities closed with VAI - Stock Titan hu, 13 Nov 2025 08
- Aldeyra stock drops on FDA delay for lead drug (ALDX:NASDAQ) - Seeking Alpha ue, 16 Dec 2025 08
- Don't Ignore The Insider Selling In Aldeyra Therapeutics - simplywall.st ue, 19 Aug 2025 07
- Aldeyra (Nasdaq: ALDX) PDUFA review of reproxalap dry eye NDA extended to Mar. 2026 - Stock Titan Mon, 15 Dec 2025 08
- Are Medical Stocks Lagging Aldeyra Therapeutics (ALDX) This Year? - Yahoo Finance ue, 03 Feb 2026 08
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -31.69M | -53.68M | -35.21M | -60.07M |
| TotalUnusualItems | 0.00 | |||
| TotalUnusualItemsExcludingGoodwill | 0.00 | |||
| NetIncomeFromContinuingOperationNetMinorityInterest | -33.85M | -55.85M | -37.54M | -62.02M |
| ReconciledDepreciation | 251.99K | 249.62K | 262.78K | 258.71K |
| EBITDA | -31.69M | -53.68M | -35.21M | -60.07M |
| EBIT | -31.94M | -53.93M | -35.47M | -60.33M |
| NetInterestIncome | 1.42M | 4.27M | 5.25M | 655.35K |
| InterestExpense | 1.91M | 1.93M | 2.07M | 1.69M |
| InterestIncome | 3.32M | 6.19M | 7.32M | 2.35M |
| NormalizedIncome | -33.85M | -55.85M | -37.54M | -62.02M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -33.85M | -55.85M | -37.54M | -62.02M |
| TotalExpenses | 35.27M | 60.12M | 42.79M | 62.68M |
| TotalOperatingIncomeAsReported | -35.27M | -60.12M | -42.79M | -62.68M |
| DilutedAverageShares | 60.06M | 59.48M | 58.94M | 58.41M |
| BasicAverageShares | 60.06M | 59.48M | 58.94M | 58.41M |
| DilutedEPS | -0.56 | -0.94 | -0.64 | -1.06 |
| BasicEPS | -0.56 | -0.94 | -0.64 | -1.06 |
| DilutedNIAvailtoComStockholders | -33.85M | -55.85M | -37.54M | -62.02M |
| NetIncomeCommonStockholders | -33.85M | -55.85M | -37.54M | -62.02M |
| NetIncome | -33.85M | -55.85M | -37.54M | -62.02M |
| NetIncomeIncludingNoncontrollingInterests | -33.85M | -55.85M | -37.54M | -62.02M |
| NetIncomeContinuousOperations | -33.85M | -55.85M | -37.54M | -62.02M |
| TaxProvision | 0.00 | |||
| PretaxIncome | -33.85M | -55.85M | -37.54M | -62.02M |
| SpecialIncomeCharges | 0.00 | |||
| NetNonOperatingInterestIncomeExpense | 1.42M | 4.27M | 5.25M | 655.35K |
| InterestExpenseNonOperating | 1.91M | 1.93M | 2.07M | 1.69M |
| InterestIncomeNonOperating | 3.32M | 6.19M | 7.32M | 2.35M |
| OperatingIncome | -35.27M | -60.12M | -42.79M | -62.68M |
| OperatingExpense | 35.27M | 60.12M | 42.79M | 62.68M |
| ResearchAndDevelopment | 25.66M | 48.22M | 29.46M | 47.31M |
| SellingGeneralAndAdministration | 9.60M | 11.89M | 13.34M | 15.37M |
| GeneralAndAdministrativeExpense | 9.60M | 11.89M | 13.34M | 15.37M |
| OtherGandA | 9.60M | 11.89M | 13.34M | 15.37M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 60.16M | 59.65M | 59.20M | 58.56M |
| ShareIssued | 60.16M | 59.65M | 59.20M | 58.56M |
| TotalDebt | 15.53M | 15.30M | 15.66M | 16.08M |
| TangibleBookValue | 44.25M | 71.00M | 119.80M | 151.01M |
| InvestedCapital | 59.50M | 86.04M | 134.94M | 166.84M |
| WorkingCapital | 43.97M | 85.47M | 125.55M | 165.66M |
| NetTangibleAssets | 44.25M | 71.00M | 119.80M | 151.01M |
| CapitalLeaseObligations | 280.54K | 271.63K | 510.81K | 249.26K |
| CommonStockEquity | 44.25M | 71.00M | 119.80M | 151.01M |
| TotalCapitalization | 44.25M | 86.00M | 119.80M | 165.93M |
| TotalEquityGrossMinorityInterest | 44.25M | 71.00M | 119.80M | 151.01M |
| StockholdersEquity | 44.25M | 71.00M | 119.80M | 151.01M |
| GainsLossesNotAffectingRetainedEarnings | 0.00 | 37.44K | 0.00 | -103.94K |
| OtherEquityAdjustments | 37.44K | -103.94K | ||
| RetainedEarnings | -483.96M | -450.11M | -394.26M | -356.72M |
| AdditionalPaidInCapital | 528.15M | 521.02M | 513.99M | 507.77M |
| CapitalStock | 60.16K | 59.65K | 59.20K | 58.56K |
| CommonStock | 60.16K | 59.65K | 59.20K | 58.56K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 27.81M | 33.60M | 28.53M | 30.28M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 0.00 | 15.00M | 6.27M | 14.92M |
| NonCurrentDeferredLiabilities | 0.00 | 6.00M | 0.00 | |
| NonCurrentDeferredRevenue | 0.00 | 6.00M | 0.00 | |
| LongTermDebtAndCapitalLeaseObligation | 15.00M | 271.63K | 14.92M | 15.63M |
| LongTermCapitalLeaseObligation | 0.00 | 271.63K | 0.00 | 125.23K |
| LongTermDebt | 15.00M | 14.92M | 15.50M | |
| CurrentLiabilities | 27.81M | 18.60M | 22.26M | 15.36M |
| CurrentDeferredLiabilities | 6.00M | 6.00M | 0.00 | |
| CurrentDeferredRevenue | 6.00M | 6.00M | 0.00 | |
| CurrentDebtAndCapitalLeaseObligation | 15.53M | 303.00K | 15.39M | 1.16M |
| CurrentCapitalLeaseObligation | 280.54K | 271.63K | 239.18K | 249.26K |
| CurrentDebt | 15.25M | 31.37K | 15.15M | 911.76K |
| OtherCurrentBorrowings | 15.25M | 31.37K | 15.15M | 911.76K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 4.27M | 4.33M | 3.09M | 3.82M |
| PayablesAndAccruedExpenses | 2.01M | 7.97M | 3.79M | 10.38M |
| CurrentAccruedExpenses | 1.85M | 7.79M | 2.45M | 10.24M |
| Payables | 158.46K | 180.45K | 1.34M | 133.62K |
| AccountsPayable | 158.46K | 180.45K | 1.34M | 133.62K |
| TotalAssets | 72.06M | 104.61M | 148.33M | 181.29M |
| TotalNonCurrentAssets | 275.86K | 534.22K | 516.58K | 268.54K |
| NonCurrentDeferredAssets | 0.00 | 267.26K | 0.00 | |
| NetPPE | 275.86K | 266.95K | 516.58K | 268.54K |
| GrossPPE | 275.86K | 266.95K | 516.58K | 268.54K |
| OtherProperties | 275.86K | 266.95K | 516.58K | 268.54K |
| CurrentAssets | 71.78M | 104.07M | 147.81M | 181.02M |
| OtherCurrentAssets | 291.92K | 301.15K | 183.15K | 442.72K |
| CurrentDeferredAssets | 1.04M | 2.21M | 4.46M | 2.61M |
| PrepaidAssets | 407.19K | 408.09K | 340.39K | 432.23K |
| Receivables | 0.00 | 3.24M | 28.77K | |
| OtherReceivables | 3.24M | 28.77K | ||
| CashCashEquivalentsAndShortTermInvestments | 70.04M | 101.15M | 142.82M | 174.30M |
| OtherShortTermInvestments | 0.00 | 46.62M | 0.00 | 29.88M |
| CashAndCashEquivalents | 70.04M | 54.53M | 142.82M | 144.42M |
| CashEquivalents | 40.47M | 30.79M | 14.31M | 9.27M |
| CashFinancial | 29.57M | 23.73M | 128.51M | 135.15M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -33.35M | -43.21M | -30.33M | -56.65M |
| RepaymentOfDebt | 0.00 | -292.50K | -1.04M | 0.00 |
| IssuanceOfCapitalStock | 0.00 | 189.81M | ||
| CapitalExpenditure | -16.32K | -7.81K | ||
| InterestPaidSupplementalData | 1.69M | 1.75M | 1.70M | 1.34M |
| EndCashPosition | 70.04M | 54.53M | 142.82M | 144.42M |
| BeginningCashPosition | 54.53M | 142.82M | 144.42M | 229.79M |
| ChangesInCash | 15.51M | -88.30M | -1.60M | -85.37M |
| FinancingCashFlow | 1.12M | -171.42K | -1.27M | 1.22M |
| CashFlowFromContinuingFinancingActivities | 1.12M | -171.42K | -1.27M | 1.22M |
| NetOtherFinancingCharges | -267.26K | -532.95K | ||
| ProceedsFromStockOptionExercised | 1.12M | 388.34K | 305.23K | 1.22M |
| NetCommonStockIssuance | 0.00 | 189.81M | ||
| CommonStockIssuance | 0.00 | 189.81M | ||
| NetIssuancePaymentsOfDebt | 0.00 | -292.50K | -1.04M | 0.00 |
| NetLongTermDebtIssuance | 0.00 | -292.50K | -1.04M | 0.00 |
| LongTermDebtPayments | 0.00 | -292.50K | -1.04M | 0.00 |
| InvestingCashFlow | 47.74M | -44.92M | 30.00M | -29.95M |
| CashFlowFromContinuingInvestingActivities | 47.74M | -44.92M | 30.00M | -29.95M |
| NetInvestmentPurchaseAndSale | 47.74M | -44.92M | 30.00M | -29.94M |
| SaleOfInvestment | 88.00M | 52.00M | 30.00M | 63.00M |
| PurchaseOfInvestment | -40.26M | -96.92M | 0.00 | -92.94M |
| NetPPEPurchaseAndSale | 0.00 | -16.32K | -7.81K | |
| PurchaseOfPPE | 0.00 | -16.32K | -7.81K | |
| OperatingCashFlow | -33.35M | -43.21M | -30.33M | -56.64M |
| CashFlowFromContinuingOperatingActivities | -33.35M | -43.21M | -30.33M | -56.64M |
| ChangeInWorkingCapital | -5.18M | 5.91M | 861.18K | -3.44M |
| ChangeInOtherWorkingCapital | 6.00M | |||
| ChangeInPayablesAndAccruedExpense | -6.36M | 3.85M | -6.87M | 316.31K |
| ChangeInAccruedExpense | -6.34M | 5.00M | -8.08M | 1.20M |
| ChangeInPayable | -21.99K | -1.16M | 1.20M | -886.08K |
| ChangeInAccountPayable | -21.99K | -1.16M | 1.20M | -886.08K |
| ChangeInPrepaidAssets | 1.18M | 2.07M | 1.73M | -3.76M |
| OtherNonCashItems | 218.26K | 177.33K | 354.19K | 331.15K |
| StockBasedCompensation | 6.09M | 7.97M | 5.75M | 8.29M |
| AssetImpairmentCharge | 267.26K | 0.00 | ||
| AmortizationOfSecurities | -1.15M | -1.67M | -14.54K | -47.24K |
| DeferredTax | 0.00 | |||
| DeferredIncomeTax | 0.00 | |||
| DepreciationAmortizationDepletion | 251.99K | 249.62K | 262.78K | 258.71K |
| DepreciationAndAmortization | 251.99K | 249.62K | 262.78K | 258.71K |
| NetIncomeFromContinuingOperations | -33.85M | -55.85M | -37.54M | -62.02M |
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for /ALDX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|